# The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

Study · id `cardio:ct-nct03129555` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03129555](<https://clinicaltrials.gov/study/NCT03129555>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03129555

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 5000 participants.

## Technical summary

Registry record NCT03129555. Randomized; single masking; primary purpose treatment. Start 2023-04-01 (actual); primary completion 2027-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 5000 participants (planned count; ClinicalTrials.gov record NCT03129555, source copy `cardio:ctgov-nct03129555-2025-05-15`, retrieved 2026-10-31)
- Started: 2023-04-01 (actual) (ClinicalTrials.gov record NCT03129555, source copy `cardio:ctgov-nct03129555-2025-05-15`, retrieved 2026-10-31)
- Primary completion: 2027-03-31 (anticipated) (ClinicalTrials.gov record NCT03129555, source copy `cardio:ctgov-nct03129555-2025-05-15`, retrieved 2026-10-31)
- Completion: 2029-03-31 (anticipated) (ClinicalTrials.gov record NCT03129555, source copy `cardio:ctgov-nct03129555-2025-05-15`, retrieved 2026-10-31)
- Countries: Denmark (ClinicalTrials.gov record NCT03129555, source copy `cardio:ctgov-nct03129555-2025-05-15`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03129555-2025-05-15`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
- Acronym: DANNOAC-VTE
- Condition: Deep Vein Thrombosis
- Condition: Pulmonary Embolism
- Intervention (Drug): Dabigatran Etexilate Oral Capsule
- Intervention (Drug): Rivaroxaban Oral Tablet
- Intervention (Drug): Edoxaban Oral Tablet
- Intervention (Drug): Apixaban Oral Tablet
- Lead sponsor: Herlev and Gentofte Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Herlev and Gentofte Hospital (`cardio:org-herlev-and-gentofte-hospital`)

## Provenance

Content hash: df076105016fe6cb2fd07265c9d71d62c92d32332b9c7a507bbe1a0b4b5c3bf9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
